Zentalis Advances Azenosertib Toward Potential Accelerated Approval with Key 2026 Milestones in Ovarian Cancer
Key Insights
Zentalis Pharmaceuticals completed enrollment in DENALI Part 2a for its investigational WEE1 (search) inhibitor azenosertib, with dose confirmation expected in the first half of 2026.
The company plans to initiate the confirmatory ASPENOVA Phase 3 trial in the first half of 2026, comparing azenosertib to standard-of-care chemotherapy in Cyclin E1 (search)-positive platinum-resistant ovarian cancer (search) patients.
DENALI Part 2 topline results are expected by year-end 2026, which could potentially support accelerated approval for treating approximately 50% of platinum-resistant ovarian cancer (search) patients who overexpress Cyclin E1 (search).
Zentalis Pharmaceuticals has completed enrollment in a pivotal dose-confirmation study for azenosertib, its investigational WEE1 (search) inhibitor targeting Cyclin E1 (search)-positive platinum-resistant ovarian cancer (search) (PROC), setting the stage for multiple critical milestones in 2026 that could advance the drug toward accelerated approval.
The San Diego-based clinical oncology company announced completion of enrollment in DENALI Part 2a, a registration-intended Phase 2 trial designed to confirm the optimal dose for azenosertib. The study enrolled approximately 30 patients at each of two dose levels: 400mg QD 5:2 and 300mg QD 5:2, using an intermittent daily dosing schedule with five days on and two days off.
Critical 2026 Development Timeline
Zentalis has outlined an aggressive timeline for 2026, beginning with dose confirmation from DENALI Part 2a expected in the first half of the year. This will be followed by initiation of ASPENOVA, a randomized Phase 3 confirmatory trial comparing azenosertib to standard-of-care chemotherapy in Cyclin E1 (search)-positive PROC patients.
"2026 represents a pivotal year for Zentalis as we advance azenosertib toward potential approval in Cyclin E1 (search)-positive platinum-resistant ovarian cancer (search) and continue to assess its role in additional indications," said Julie Eastland, Chief Executive Officer of Zentalis.
The company expects topline readout from DENALI Part 2 by year-end 2026, which could potentially support an accelerated approval application, subject to FDA feedback. The ASPENOVA Phase 3 trial is planned to run concurrently with DENALI Part 2.
Targeting an Underserved Patient Population
Azenosertib represents a potentially first-in-class, selective, and orally bioavailable inhibitor of WEE1 (search), a master regulator of cell cycle checkpoints. The drug works by enabling cell cycle progression despite high levels of DNA damage, leading to mitotic catastrophe and cancer cell death.
The therapy specifically targets patients with Cyclin E1 (search)-positive PROC, a biomarker-selected population comprising approximately 50% of PROC patients. Currently, no approved treatment option exists specifically for this biomarker-selected population, representing a significant unmet medical need.
"We remain focused on executing our strategy to bring this potentially first-in-class, non-chemo, oral therapy to the approximately 50% of PROC patients who are Cyclin E1 (search)-positive—a population with significant unmet needs," Eastland added.
Strong Clinical Foundation and Regulatory Alignment
Zentalis has established a solid foundation for azenosertib development through strong data across three trials in PROC. In Part 1b of DENALI at the 400mg 5:2 dosing schedule, azenosertib demonstrated clinically meaningful results with a manageable safety profile. Importantly, Cyclin E1 (search) overexpression, regardless of CCNE1 gene amplification status, was observed as a predictive biomarker to identify patients who could potentially benefit from treatment.
The company has aligned with the FDA on the design for ASPENOVA, the Phase 3 randomized confirmatory trial. The DENALI trial design was also aligned with the FDA, with Part 2 designed specifically for accelerated approval, pending study outcome and regulatory discussions.
Financial Position Supports Development Timeline
Zentalis maintains a strong financial foundation to support its development timeline. As of September 30, 2025, the company had cash, cash equivalents and marketable securities of $280.7 million. Following strategic restructuring to focus pipeline and resources, Zentalis believes its existing cash position provides an estimated runway into late 2027, extending beyond the anticipated DENALI Part 2 topline readout.
Mechanism of Action and Broader Potential
WEE1 (search) acts as a master regulator of the G1-S and G2-M cell cycle checkpoints through negative regulation of both CDK1 (search) and CDK2 (search), preventing replication of cells with damaged DNA. By inhibiting WEE1, azenosertib enables cell cycle progression despite high DNA damage levels, resulting in DNA damage accumulation and leading to mitotic catastrophe and cancer cell death.
Beyond the Cyclin E1 (search)-positive PROC setting, Zentalis plans to continue evaluating azenosertib's potential in earlier lines of ovarian cancer (search) and other indications where WEE1 (search) inhibition may play a meaningful therapeutic role.